References

1. B. Rosenberg, L. Van Camp, J.E. Trosko and V.H. Mansour, Nature 222, 385-386 (1969).

2. E. Wong and C.M. Giandomenico, Chem. Rev. 99, 2451-2466 (1999).

3. Y.P. Ho, S.C.F. AuYeung and K.K.W. To, Med. Res. Rev. 23, 633-655 (2003).

4. M.S. Highley and A.H. Calvert, in: Platinum-Based Drugs in Cancer Therapy, L.R. Kelland and N.P. Farrell (Eds), Humana Press Inc., Totowa/NJ, pp. 171-194 (2000).

6. P.J. O'Dwyer, J.P. Stevenson and S.W. Johnson, Drugs 59, 19-27 (2000).

7. L.R. Wiseman, J.C. Adkins, G.L. Plosker and K.L. Goa, Drugs Aging 14, 459-475

8. F. Levi, G. Metzger, C. Massari and G. Milano, Clin. Pharmacokinetics 38, 1-21

9. B. Desoize and C. Madoulet, Crit. Rev. Oncol. Hematol. 42, 317-325 (2002).

10. N.P. Johnson, J.-L. Butour, G. Villani etal., Prog. Clin. Biochem. Med. 10, 1-24 (1989).

11. V. Brabec, Prog. Nucleic Acid Res. Mol. Biol. 71, 1-68 (2002).

12. G. Villani, N.T. Le Gac and J.-S. Hoffmann, in: Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, B. Lippert (Ed.), VHCA, Wiley-CH, Zürich, Weinheim, pp. 135-157 (1999).

13. Y. Jungand and S.J. Lippard, J. Biol. Chem. 278, 52084-52092 (2003).

14. M. Kartalou and J.M. Essigmann, Mutat. Res. 478, 23-43 (2001).

15. V. Brabec and J. Kasparkova, Drug Resist. Updates 5, 147-161 (2002).

16. S.W. Johnson, K.V. Ferry and T.C. Hamilton, Drug Resist. Updates 1, 243-254 (1998).

17. M. Kartalou and J.M. Essigmann, Mutat. Res. 478, 1-21 (2001).

18. A.L. Pinto and S.J. Lippard, Proc. Natl. Acad. Sci. USA 82, 4616^620 (1985).

19. B. Salles, J.L. Butour, C. Lesca and J.P. Macquet, Biochem. Biophys. Res. Commun. 112, 555-563 (1983).

20. M.A. Fuertes, J. Castilla, C. Alonso and J.M. Perez, Curr. Med. Chem. 10, 257-266 (2003).

21. V.M. Gonzalez, M.A. Fuertes, C. Alonso and J.M. Perez, Mol. Pharmacol. 59, 657 663 (2001).

22. F.A. Blommaert, H.C.M. van Dijk-Knijnenburg, F.J. Dijt etal., Biochemistry 34, 8474-8480 (1995).

23. O. Vrana, V. Brabec and V. Kleinwächter, Anticancer Drug Des. 1, 95-109 (1986).

24. J.M. Woynarowski, W.G. Chapman, C. Napier etal., Mol. Pharmacol. 54, 770-777

25. J.M. Woynarowski, S. Faivre, M.C.S. Herzig etal., Mol. Pharmacol. 58, 920-927 (2000).

26. J.T. Reardon, A. Vaisman, S.G. Chaney and A. Sancar, Cancer Res. 59, 3968-3971

27. B. Spingler, D.A. Whittington and S.J. Lippard, Inorg. Chem. 40, 5596-5602 (2001).

28. A. Vaisman, S.E. Lim, S.M. Patrick etal., Biochemistry 38, 11026-11039 (1999).

29. K. Kawanishi, Y. Miyagi, J. Yamamoto etal., Cancer Chemother. Pharmacol. 47, 303 308 (2001).

30. N. Farrell, L.R. Kelland, J.D. Roberts and M. Van Beusichem, Cancer Res. 52, 5065-5072 (1992).

31. V. Brabec, V. Kleinwächter, J.L. Butour and N.P. Johnson, Biophys. Chem. 35, 129-141 (1990).

32. V. Brabec and M. Leng, Proc. Natl. Acad. Sci. USA 90, 5345-5349 (1993).

33. M. Leng, A. Schwartz and M.J. Giraud-Panis, in: Platinum-Based Drugs in Cancer Therapy, L.R. Kelland and N.P. Farrell (Eds), Humana Press Inc., Totowa/NJ, pp. 63 85 (2000).

34. M. Coluccia, F. Nassii, F. Loseto etal., J. Med. Chem. 36, 510-512 (1993).

35. V. Brabec, O. Vrana, O. Novakova etal., Nucleic Acids Res. 24, 336-341 (1996).

36. O. Novakova, J. Kasparkova, J. Malina etal., Nucleic Acids Res. 31, 6450-6460 (2003).

37. G. Natile and M. Coluccia, Coord. Chem. 216, 383-410 (2001).

38. J. Kasparkova, O. Novakova, N. Farrell and V. Brabec, Biochemistry 42, 792 800 (2003).

39. V. Brabec, K. Neplechova, J. Kasparkova and N. Farrell, J. Biol. Inorg. Chem. 5, 364-368 (2000).

40. J. Kasparkova, V. Marini, Y. Najajreh etal., Biochemistry 42, 6321-6332 (2003).

41. J. Kasparkova, O. Novakova, V. Marini etal., J. Biol. Chem. 278, 47516^7525 (2003).

42. J.M. Perez, E.I. Montero, A.M. Gonzalez etal., J. Med. Chem. 43, 2411-2418 (2000).

43. E.I. Montero, S. Diaz, A.M. Gonzalez-Vadillo etal., J. Med. Chem. 42, 4264-4268 (1999).

44. N. Farrell, in: Platinum-Based Drugs in Cancer Therapy, L.R. Kelland and N.P. Farrell (Eds), Humana Press Inc., Totowa/NJ, pp. 321-338 (2000).

45. V. Brabec, J. Kasparkova, O. Vrana etal., Biochemistry 38, 6781-6790 (1999).

46. J. Kasparkova, J. Zehnulova, N. Farrell and V. Brabec, J. Biol. Chem. 277, 48076-48086 (2002).

47. J. Zehnulova, J. Kasparkova, N. Farrell and V. Brabec, J. Biol. Chem. 276, 22191-22199 (2001).

48. E. Fokkema, H.J.M. Groen, M.N. Helder etal., Biochem. Pharmacol. 63, 1989-1996 (2002).

49. K.J. Mellish, C.F.J. Barnard, B.A. Murrer and L.R. Kelland, Int. J. Cancer 62, 717-723 (1995).

50. L.R. Kelland, in: Platinum-Based Drugs in Cancer Therapy, L.R. Kelland and N.P. Farrell (Eds), Humana Press Inc., Totowa/NJ, pp. 299-319 (2000).

51. P. Muller, B. Schroder, J.A. Parkinson etal., Angew. Chem. Int. Ed. 42, 335-339 (2003).

52. J. Kasparkova, F.S. Mackay, V. Brabec and P.J. Sadler, J. Biol. Inorg. Chem. 8, 741-745 (2003).

53. W.I. Sundquist and S.J. Lippard, Coord. Chem. Rev. 100, 293-322 (1990).

54. M. Leng and V. Brabec, in: DNA Adducts: Identification and Biological Significance, K. Hemminki, A. Dipple, D.E.G. Shuker, F.F. Kadlubar, D. Segerbäck and H. Bartsch (Eds), International Agency for Research on Cancer, Lyon, pp. 339-348 (1994).

55. B.E. Bowler, L.S. Hollis and S.J. Lippard, J. Am. Chem. Soc. 106, 6102-6104 (1984).

56. M. Lee, J.E. Simpson, A.J. Burns etal., Med. Chem. Res. 6, 365-371 (1996).

57. H. Loskotova and V. Brabec, Eur. J. Biochem. 266, 392-402 (1999).

58. H. Kostrhunova and V. Brabec, Biochemistry 39, 12639-12649 (2000).

59. A.A. Bogdanov, C. Martin, A.V. Bogdanova etal., Bioconjug. Chem. 7, 144-149 (1996).

60. Anon., Expert Opin. Ther. Patents 9, 661-662 (May 1999).

61. M. Bouma, B. Nuijen, D.R. Stewart etal., Anticancer Drugs 13, 915-924 (2002).

62. I. Han, A.R. Khokhar and R. PerezSoler, Cancer Chemother. Pharmacol. 39, 17-24 (1996).

63. A. Mori, S.P. Wu, I. Han etal., Cancer Chemother. Pharmacol. 37, 435-444 (1996).

64. M.S. Newman, G.T. Colbern, P.K. Working etal., Cancer Chemother. Pharmacol. 43, 1-7 (1999).

65. T. Boulikas and M. Vougiouka, Oncol. Rep. 10, 1663-1682 (2003).

66. K.N.J. Burger, R.W.H.M. Staffhorst, H.C. deVijlder etal, Nat. Med. 8, 81-84 (2002).

67. R.C. Taylor and S.G. Ward, in: Lectures in Bioinorganic Chemistry, M. Nicolini and L. Sindellari (Eds), Raven Press, New York, pp. 63-90 (1991).

68. M. Coluccia, A. Boccarelli, C. Cermelli etal., Metal-Based Drugs 2, 249-256 (1995).

69. N.A. Jones, J. Turner, A.J. McIlwrath etal., Mol. Pharmacol. 53, 819-826 (1998).

70. M. Hussain, U. Vaishampayan, W. Du etal, J. Clin. Oncol. 19, 2527-2533 (2001).

71. A. Vasuratna, A.P. Kudelka, C.L. Edwards etal., Anticancer Drugs 9, 283-285 (1998).

72. R.P. Perez, Eur. J. Cancer 34, 1535-1542 (1998).

74. M. Fujita, T. Fujita, T. Kodama etal., Int. J. Oncol. 17, 393-397 (2000).

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment